从资金流向上来看，当日医疗器械板块主力资金净流出2.02亿元，游资资金净流出3162.95万元，散户资 金净流入2.34亿元。医疗器械板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，11月14日医疗器械板块较上一交易日下跌0.22%，天益医疗领跌。当日上证指数报收于 3990.49，下跌0.97%。深证成指报收于13216.03，下跌1.93%。医疗器械板块个股涨跌见下表： ...

中信保诚多策略混合(LOF)A（165531）成立日期2017年6月16日，最新规模11.33亿。今年以来收益 48.93%，同类排名1166/8140；近一年收益46.65%，同类排名762/8056；成立以来收益152.18%。 中信保诚多策略混合(LOF)A（165531）基金经理为王颖。 截至发稿，王颖累计任职时间8年274天，现任基金资产总规模49.04亿元，任职期间最佳基金回报 53.77%， 任职期间最差基金回报-8.42%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月14日，天益医疗跌5.04%，截至发稿，报60.80元/股，成交3032.49万元，换手率1.70%，总市值 35.84亿元。 资料显示，宁波天益医疗器械股份有限公司位于浙江省宁波市东钱湖旅游度假区莫枝北路788号，成立 日期1998年3月12日，上市日期2022年4月7日，公司主营业务涉及血液净化及病房护理领域医用高分子 耗材等医疗器械的研发、生产与销售。主营业务收入构成为：血液 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 64.03 | -1.94% | -2040.35万 | -7.20% | 1280.76万 | 4.52% | 759.59万 | 2.68% | | 2025-11-12 | 65.30 11.34% | | -90.71万 | -0.31% | 1813.46万 | 6.16% | -1722.75万 | -5.85% | | 2025-11-11 | 58.65 -1.56% | | -233.23万 | -2.37% | 196.65万 | 1.99% | 36.59万 | 0.37% | | 2025-11-10 | 59.58 7.35% | | 450.32万 | 2.11% | -598.89万 | -2.80% | 148.57万 | 0.70% | | 2025-11-07 | 55.50 -4.31% | | -881.10万 ...

证券日报网讯天益医疗11月12日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东总 数为5，689户。 （文章来源：证券日报） ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Market Overview - The medical device sector experienced a decline of 0.17% on November 7, with Tianyi Medical leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - Notable gainers in the medical device sector included: - Aomei Medical: Closed at 12.71, up 10.04% with a trading volume of 284,600 shares and a turnover of 351 million yuan [1] - Innotec: Closed at 34.35, up 7.08% with a trading volume of 91,900 shares and a turnover of 312 million yuan [1] - Hualan Biological: Closed at 46.00, up 4.55% with a trading volume of 67,400 shares and a turnover of 305 million yuan [1] - Conversely, Tianyi Medical saw a decline of 4.31%, closing at 55.50 with a trading volume of 17,800 shares and a turnover of approximately 99.91 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 110 million yuan from institutional investors, while retail investors contributed a net inflow of 380 million yuan [2] - Key stocks with significant capital flow included: - Zhend Medical: Net inflow of 11.9 million yuan from institutional investors, but a net outflow of 14.7 million yuan from retail investors [3] - Aomei Medical: Net inflow of 93.59 million yuan from institutional investors, with a net outflow of 38.13 million yuan from retail investors [3] - Yuyue Medical: Net inflow of 81.36 million yuan from institutional investors, with a net outflow of 13.30 million yuan from retail investors [3]

Core Viewpoint - Tianyi Medical has received EU MDR certification for multiple products, indicating compliance with the latest EU medical device regulations, which enhances its market access and sales potential in Europe [1][3]. Trading Information Summary - On November 5, 2025, Tianyi Medical's stock closed at 58.8 yuan, up by 5.0%, with a turnover rate of 12.94% and a trading volume of 37,500 shares, resulting in a transaction value of 216 million yuan [1]. - The net inflow of main funds was 18.84 million yuan, while speculative funds saw a net inflow of 13.12 million yuan; however, retail investors experienced a net outflow of 31.97 million yuan [1][3]. Company Announcement Summary - Tianyi Medical has obtained EU MDR certification for products including Extracorporeal Blood Tubing Set, Oral/Enteral Syringe, Oral/Enteral Syringe with ENFit connector, and Arterial-Venous Fistula Needle Set, with the latter being a newly certified product [1][3]. - The certification, effective from November 4, 2025, and valid until January 5, 2028, signifies that the company's products meet the latest EU regulatory requirements, facilitating their promotion and sales in overseas markets [1].

Group 1 - Triangle Defense signed a gas turbine project development and framework order agreement with Siemens Energy [1] - The development agreement allows Triangle Defense to qualify for supplying specific items to Siemens Energy, detailing technical prerequisites and standards [1] - Triangle Defense specializes in the research, production, and sales of forged products in aviation, aerospace, and shipping industries [1] Group 2 - Aerospace Hongtu was suspended from military procurement for three years due to alleged violations during a procurement activity [2] - The suspension will last from July 6, 2024, to July 6, 2027, affecting the company's participation in military material procurement [2] - Aerospace Hongtu focuses on satellite operations and data collection [3] Group 3 - Kaili Medical's executives purchased a total of 460,000 shares, investing approximately 13.15 million yuan [4] - The average purchase prices were 28.70 yuan and 28.53 yuan per share [4] - Kaili Medical is engaged in the research, production, and sales of medical diagnostic and treatment equipment [5] Group 4 - Muyuan Foods reported a 22.28% year-on-year decline in sales revenue from live pigs in October, totaling 10.33 billion yuan [6] - The average selling price of live pigs decreased by 32.73% year-on-year to 11.55 yuan per kilogram [6] - Muyuan Foods is involved in pig farming and slaughtering [7] Group 5 - Niuwei Co. plans to acquire 40% of its subsidiary Dongwu Machinery for 139 million yuan, aiming for full ownership [8] - Niuwei Co. specializes in the research, manufacturing, and sales of industrial valves [9] Group 6 - Jinlong Automobile reported a 14.71% year-on-year decline in bus sales in October, with 4,121 units sold [10] - Jinlong Automobile focuses on the production and sales of bus products [10] Group 7 - ST Tianshan reported a 242.54% year-on-year increase in sales revenue from live livestock in October, totaling 13.35 million yuan [11] - The company sold 1,367 head of livestock, marking a significant increase compared to previous periods [11] - ST Tianshan is involved in the breeding and sales of cattle and dairy products [12] Group 8 - Ningbo Port expects a 12.4% year-on-year increase in container throughput in October, reaching 4.56 million TEUs [13] - The total cargo throughput is projected to be 99.6 million tons, a 5.3% increase year-on-year [13] - Ningbo Port engages in port handling and logistics services [13] Group 9 - Amcare Pharma received approval for supplementary drug applications and clinical trials for its products [14] - The company is focused on new drug development and utilizes a MAH model for production [14] Group 10 - Lude Environment plans to change its stock name to "Lude Technology" while keeping its full name and stock code unchanged [15] - The company specializes in waste treatment and resource utilization technologies [15] Group 11 - Hualan Co. plans to increase its stake in the company by investing between 30 million and 60 million yuan [16] - The maximum purchase price is set at 58.08 yuan per share [16] - Hualan Co. focuses on the development and sales of packaging materials for injectable drugs [16] Group 12 - Caina Co. is using 140 million yuan of idle funds to purchase structured deposits from a bank, with expected annual yields between 0.70% and 1.85% [17] - Caina Co. specializes in the research, production, and sales of injection and laboratory consumables [17] Group 13 - Zhenghong Technology reported a 52.80% year-on-year decrease in sales revenue from live pigs in October, totaling 4.32 million yuan [18] - The company sold 400 head of pigs, marking a significant decline compared to previous periods [18] - Zhenghong Technology is involved in feed production and pig farming [18] Group 14 - Caida Securities received approval from the CSRC to issue bonds totaling up to 6 billion yuan [19] - The company is engaged in securities brokerage, investment banking, and asset management [19] Group 15 - Jiayuan Technology signed a copper foil supply framework agreement with CATL, establishing a long-term partnership [20] - The agreement includes collaboration in the supply and production of materials for new battery technologies [20] Group 16 - Haikong Group announced the resignation of its general manager due to personal career planning [21] - The company is involved in automotive passenger transport and related services [21] Group 17 - Beizhi Technology's application to acquire 100% of Suzhou Suike Intelligent Technology has been accepted by the Shanghai Stock Exchange [22] - The company specializes in intelligent logistics systems and equipment [22] Group 18 - Yikang Pharma's subsidiary received approval for clinical trials of a new injection for chronic hepatitis B [23] - The company focuses on the production and sales of raw and formulated pharmaceutical products [23] Group 19 - Hengyuan Coal Power plans to acquire 100% of two coal companies for 440 million yuan [24] - The acquisition includes assuming debts totaling 1.137 billion yuan [24] - Hengyuan Coal Power is involved in coal mining and sales [24] Group 20 - Yangpu Medical announced the cancellation of a production arrangement for a medical device [25] - The company specializes in precision medical and testing services [25] Group 21 - Kailong High-Tech plans to establish a 195 million yuan industry fund focusing on unlisted companies [26] - The company is involved in air pollution control and new energy management systems [26] Group 22 - Yingli Co. received approval for its application to acquire a majority stake in a company [27] - The company specializes in precision electronic components and related manufacturing [27] Group 23 - Tianyi Medical's arterial-venous puncture device received EU MDR certification, valid until January 2028 [28] - The company focuses on medical devices for blood purification and care [28] Group 24 - Chuangyuan Co. appointed a new president, effective until the end of the current board term [29] - The company specializes in the design and production of paper products [29] Group 25 - Shanghai Laishi's new indication for a drug received clinical trial approval [30] - The company focuses on the production and sales of blood products [30] Group 26 - Fengmao Co. plans to issue convertible bonds to raise up to 520 million yuan for expansion and working capital [31] - The company specializes in precision rubber components [31] Group 27 - Yinuo Si's shareholder plans to transfer 3% of the company's shares through an inquiry process [32] - The company provides comprehensive R&D services in the biopharmaceutical sector [32] Group 28 - Phoenix Shipping plans to use up to 50 million yuan of idle funds for cash management [33] - The company is involved in dry bulk shipping and logistics services [33] Group 29 - Xingyuan Zhuomei received a notification to supply magnesium alloy components worth 2.021 billion yuan to a new energy vehicle manufacturer [34] - The project is expected to start mass production in the third quarter of 2026 [34] Group 30 - Landai Technology's subsidiary plans to sell electric drive assembly assets for 110 million yuan [35] - The company specializes in power transmission and display technology [35] Group 31 - Yuexiu Capital plans to distribute a cash dividend of 0.90 yuan per share [36] - The company is involved in asset management and private equity [36] Group 32 - Northeast Securities plans to distribute a cash dividend of 1.00 yuan per share, totaling 234 million yuan [37] - The company focuses on wealth management and investment banking [37] Group 33 - Jinguang Electric won a bid for a project from the State Grid worth 21.7976 million yuan [38] - The company specializes in the research and manufacturing of power distribution equipment [39] Group 34 - Huarong Co. plans to repurchase shares worth between 40 million and 125 million yuan [40] - The company focuses on the production and sales of explosion-proof electrical equipment [40] Group 35 - Baiyang Pharma signed a distribution agreement for a blood product, gaining exclusive rights in specific markets [41] - The company specializes in the development and commercialization of medical innovations [41] Group 36 - Li Qun Co.'s director plans to reduce his stake by up to 71,000 shares due to personal financial needs [42] - The company is involved in retail and logistics services [42] Group 37 - Su Li Co.'s shareholder plans to reduce his stake by up to 0.48% of the company's shares [43] - The company specializes in the production and sales of fine chemical products [43] Group 38 - Shenzhen Ruijie obtained a commitment letter for a stock repurchase loan of up to 15.3 million yuan [44] - The company provides project management and evaluation services [44] Group 39 - Fudan Zhangjiang's shareholder plans to reduce his stake by up to 1% of the company's shares [45] - The company focuses on biopharmaceutical research and development [45] Group 40 - Ningbo Zhongbai's shareholder plans to reduce his stake by up to 1% of the company's shares [46] - The company is involved in retail and wholesale operations [46] Group 41 - Jingyi Co. announced a change in control due to a judicial auction of shares [47] - The company specializes in copper processing and digital carbon services [47] Group 42 - Luoping Zinc Electric's subsidiary obtained a new safety production license for mining operations [48] - The company focuses on hydropower and mining activities [48]

Core Viewpoint - Tianyi Medical (301097.SZ) has received the EU Medical Device Regulation (MDR) certification for several of its products, indicating compliance with the latest EU medical device regulations and enabling continued legal sales in relevant overseas markets [1] Product Certification - The certified products include: - Extracorporeal Blood Tubing Set - Oral/Enteral Syringe - Oral/Enteral Syringe with ENFit connector - Arterial-Venous Fistula Needle Set [1] Market Implications - The acquisition of MDR certification allows the company to meet the latest market entry conditions in the EU, which is expected to enhance the promotion and sales of its products in corresponding markets [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received the EU Medical Device Regulation (MDR) certification for several of its products, indicating compliance with the latest EU medical device regulations and enabling continued legal sales in relevant overseas markets [1] Product Certification - The certified products include: - Extracorporeal Blood Tubing Set - Oral/Enteral Syringe - Oral/Enteral Syringe with ENFit connector - Arterial-Venous Fistula Needle Set [1] Market Implications - The transition from the previous EU MDD certification to the new MDR certification allows the company to meet the latest market entry requirements in the EU, which is expected to enhance the promotion and sales of its products in the corresponding markets [1]